Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA influenza vaccine
- Development stage
- Phase 2
- Lead developer
- AIM Vaccine Co.
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
This mRNA-based influenza vaccine is a prophylactic candidate developed by Ningbo Rong'an Biological Pharmaceutical, a subsidiary of AIM Vaccine Co., Ltd. Utilizing an mRNA technology platform, the vaccine is designed to induce immune responses against influenza viruses by delivering messenger RNA that encodes viral antigens, typically the hemagglutinin protein. This approach aims to provide broader and more rapid protection compared to traditional egg-based or cell-based manufacturing processes. The vaccine is currently in Phase 1 clinical development, following the successful application for clinical trial approval in China.
- Other names
- messenger ribonucleic acid influenza vaccinemRNA seasonal influenza vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on mRNA influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA influenza vaccine.